Login to Your Account

Pozen Stumbles, Endo Delayed

Players Still Trying To Widen Market For Migraine Therapy

By Randall Osborne

Monday, August 20, 2007
As one of the latest efforts to stir the stagnated migraine market - Pozen Inc.'s combination therapy Trexima, which pairs sumatriptan with the non-steroidal anti-inflammatory drug naproxen - continues to have trouble, Endo Pharmaceuticals Inc.'s Frova (frovatriptan) might be able to make headway. But it's too early to put a lot of money on that bet. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription